Russell Karp - Concepedia

Concepedia

Author

Russell Karp

Clovis Oncology (United States)ORCID

Also Known As

R. Karp, R. M. Karp, R.M. Karp, RUSSELL KARP, Russell Karp, Russell M Karp, Russell M. Karp

73

Publications

1.8K

Citations

13

H-Index

47

Concepts

All Affiliations

Clovis Oncology (United States)Case Western Reserve University Tris Pharma (United States)United States Military Academy University Hospitals of Cleveland

RK

About

Russell Karp is an author at Clovis Oncology (United States) specializing in medicine, pharmacology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	333
2	Biochemistry	3	3	193
3	Natural Sciences	2	2	177
4	Health Sciences	1	1	19
5	Allergy	1	1	10

Russell Karp

×

16

Publications

1.8K

Citations

13

H-Index

	Year	Citations
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC Annette O. Walter, Robert Tjin Tham Sjin, Henry J. Haringsma, Cancer Discovery	2013	622
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs Susannah L. Hewitt, Ailin Bai, D. R. Shackleton Bailey, Science Translational Medicine	2019	286
Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans Erica N Evans, Richland Tester, Sharon Aslanian, Journal of Pharmacology and Experimental Therapeutics	2013	219
Intratumoral IL12 mRNA Therapy Promotes TH1 Transformation of the Tumor Microenvironment Susannah L. Hewitt, D. R. Shackleton Bailey, John Zielinski, Clinical Cancer Research	2020	206
Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine Margit Hagel, Deqiang Niu, Thia St Martin, Nature Chemical Biology Selective Irreversible InhibitionBiochemistryProtein FoldingNatural SciencesMedicine	2010	92
Discovery of a Potent and Isoform-Selective Targeted Covalent Inhibitor of the Lipid Kinase PI3Kα Mariana Nacht, Lixin Qiao, Michael P. Sheets, Journal of Medicinal Chemistry Drug TargetChemical BiologyCancer BiologyTumor BiologyMolecular Pharmacology	2013	85
<i>In Vitro</i> and <i>In Vivo</i> Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing Robert Tjin Tham Sjin, Kwangho Lee, Annette O. Walter, Molecular Cancer Therapeutics Drug TargetingNovel TherapyNormal Lung TissueMedicineCancer Growth	2014	70
Estrogen Receptor-β Expression in Relation to the Expression of Luteinizing Hormone Receptor and Cytochrome P450 Enzymes in Rat Ovarian Follicles1 Bagna Bao, Narender Kumar, Russell Karp, Biology of Reproduction	2000	58
Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI‐2458 Gerhard Hannig, Sylvie G. Bernier, Jennifer Hoyt, Arthritis & Rheumatism	2007	29
A Novel Methionine Aminopeptidase-2 Inhibitor, PPI-2458, Inhibits Non–Hodgkin's Lymphoma Cell Proliferation <i>In vitro</i> and <i>In vivo</i> Andrew C. Cooper, Russell Karp, Edward J. Clark, Clinical Cancer Research	2006	20

Page 1